Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (ALD) is a progressive neurodegenerative disease caused by mutations in ABCD1, the peroxisomal very long-chain fatty acid (VLCFA) transporter. ABCD1 deficiency results in accumulation of saturated VLCFAs. A drug screen using a phenotypic motor assay in a zebrafish ALD model identified chloroquine as the top hit. Chloroquine increased expression of stearoyl-CoA desaturase-1 (scd1), the enzyme mediating fatty acid saturation status, suggesting that a shift toward monounsaturated fatty acids relieved toxicity. In human ALD fibroblasts, chloroquine also increased SCD1 levels and reduced saturated VLCFAs. Conversely, pharmacological inhibition of SCD1 expression led to an increase in saturated VLCFAs, and CRISPR knockout of scd1 in zebrafish mimicked the motor phenotype of ALD zebrafish. Importantly, saturated VLCFAs caused ER stress in ALD fibroblasts, whereas monounsaturated VLCFA did not. In parallel, we used liver X receptor (LXR) agonists to increase SCD1 expression, causing a shift from saturated toward monounsaturated VLCFA and normalizing phospholipid profiles. Finally, Abcd1-/y mice receiving LXR agonist in their diet had VLCFA reductions in ALD-relevant tissues. These results suggest that metabolic rerouting of saturated to monounsaturated VLCFAs may alleviate lipid toxicity, a strategy that may be beneficial in ALD and other peroxisomal diseases in which VLCFAs play a key role.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The zebrafish reference genome sequence and its relationship to the human genome.
Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., Collins, J. E., Humphray, S., McLaren, K., Matthews, L., et al. (2013) · Nature · doi:10.1038/nature12111 · Cited by 5,100
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202
Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604 · cited 1×
“For example, we currently do not know whether treatment of the VLCFA levels (58, 59).”
BackgroundSelf-citationEngelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
Self-citationQualitative alteration in substrate specificity of mitochondrial monoamine oxidase in brain
Moskvitina, T. A., Kamyshanskaya, N. S., Kaverina, L. P., & Gorkin, V. Z. (1976) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1976.tb04462.x · Cited by 440
Miller, W. P., Rothman, S. M., Nascene, D., Kivisto, T., DeFor, T. E., Ziegler, R. S., Eisengart, J., Leiser, K., Raymond, G., Lund, T. C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329235 · Cited by 290
Adrenoleukodystrophy—Neuroendocrine pathogenesis and redefinition of natural history
Kemp, S., Huffnagel, I. C., Linthorst, G. E., Wanders, R. J., & Engelen, M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.90 · Cited by 275
Self-citationGene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Self-citationX-linked adrenoleukodystrophy in women: A cross-sectional cohort study
Engelen, M., Barbier, M., Dijkstra, I. M. E., Schür, R., de Bie, R. M. A., Verhamme, C., Dijkgraaf, M. G. W., Aubourg, P. A., Wanders, R. J. A., van Geel, B. M., et al. (2014) · Brain · doi:10.1093/brain/awt361 · Cited by 234
Self-citationSingh, I., Moser, A. E., Moser, H. W., & Kishimoto, Y. (1984) · Pediatric Research · doi:10.1203/00006450-198403000-00016 · Cited by 234
The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233
Self-citationPujol, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.499 · Cited by 214 · cited 2×
“Additional studies into the mechanism or mechanisms of action of CQ and LXR agonists in ALD and fatty acid saturation status and identification of compounds with lower toxicity Abcd1–/y mice with the LXR agonist TO901317 for longer than 8 months would prevent the late-onset axonal degeneration similar to that seen in…”
BackgroundResultEarly oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn085 · Cited by 214 · cited 2×
“In human fibroblasts, SCD1 activation increases the ratio of monounsaturated to saturated VLCFA; our work and that of others shows that exposure of saturated VLCFA to ALD cells causes oxidative stress, mitochondrial dysfunction, and an increase in the ER stress response (23, 25, 27, 28, 52).”
BackgroundSelf-citationHo, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118182 · Cited by 199 · cited 1×
“Free fatty acids in the form of VLCFAs are more than 20 carbons in chain length, are not easily separated from membranes, and are thereby thought to disrupt membrane structure and cause ER stress (23, 28, 51).”
BackgroundHein, S., Schonfeld, P., Kahlert, S., & Reiser, G. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn066 · Cited by 180 · cited 1×
“For example, injection of C24:0-lysophosphatidylcholine (C24:0LPC), but not C16:0-LPC (C16:0-LPC) into mouse brain resulted in widespread microglial activation and apoptosis (18, 19).”
BackgroundIs microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?
Eichler, F. S., Ren, J., Cossoy, M., Rietsch, A. M., Nagpal, S., Moser, A. B., Frosch, M. P., & Ransohoff, R. M. (2008) · Annals of Neurology · doi:10.1002/ana.21391 · Cited by 178
Self-citationHubbard, W. C., Moser, A. B., Liu, A. C., Jones, R. O., Steinberg, S. J., Lorey, F., Panny, S. R., Vogt Jr., R. F., Macaya, D., & Turgeon, C. T. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.03.010 · Cited by 177 · cited 1×
“Interestingly, the levels of C26:0-LPC, the marker that is used in newborn screening to detect ALD (47, 64), are completely normalized in ALD fibroblasts upon treatment with TO901317.”
BackgroundThe role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170 · cited 3×
“To investigate the pathway underlying the elevated levels of C26:0, we had previously developed a method to measure de novo D3-C26:0 synthesis in whole cells using 3 days of treatment with deuterium-labeled LCFA C16:0 (D3-C16:0) (20).”
BackgroundMethodSelf-citationAnalysis of very long-chain fatty acids using electrospray ionization mass spectrometry
Valianpour, F., Selhorst, J. J. M., van Lint, L. E. M., van Gennip, A. H., Wanders, R. J. A., & Kemp, S. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00098-2 · Cited by 150 · cited 3×
“trometry, as described previously (42).”
BackgroundMethodSelf-citationHuffnagel, I. C., Laheji, F. K., Aziz-Bose, R., Tritos, N. A., Marino, R., Linthorst, G. E., Kemp, S., Engelen, M., & Eichler, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01307 · Cited by 147
Self-citationDubey, P., Raymond, G. V., Moser, A. B., Kharkar, S., Bezman, L., & Moser, H. W. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.10.067 · Cited by 145 · cited 1×
“In childhood, around 50% of affected males develop primary adrenal insufficiency before the age of 10 (10, 11) and 30% to 35% of affected males develop a fatal cerebral inflammatory disease (cerebral ALD) (9, 12).”
BackgroundWiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145
Self-citationLópez-Erauskin, J., Galino, J., Ruiz, M., Cuezva, J. M., Fabregat, I., Cacabelos, D., Boada, J., Martínez, J., Ferrer, I., Pamplona, R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt186 · Cited by 125 · cited 1×
“In human fibroblasts, SCD1 activation increases the ratio of monounsaturated to saturated VLCFA; our work and that of others shows that exposure of saturated VLCFA to ALD cells causes oxidative stress, mitochondrial dysfunction, and an increase in the ER stress response (23, 25, 27, 28, 52).”
BackgroundDisease progression in women with X-linked adrenoleukodystrophy is slow
Huffnagel, I. C., Dijkgraaf, M. G. W., Janssens, G. E., van Weeghel, M., van Geel, B. M., Poll-The, B. T., Kemp, S., & Engelen, M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1008-6 · Cited by 100 · cited 2×
“In adulthood, virtually all male patients and more than 80% of affected women develop a chronic progressive myelopathy (15, 16) for which no disease-modifying therapy is available (9).”
BackgroundMethodSelf-citationHuffnagel, I. C., van de Beek, M.-C., Showers, A. L., Orsini, J. J., Klouwer, F. C. C., Dijkstra, I. M. E., Schielen, P. C., van Lenthe, H., Wanders, R. J. A., Vaz, F. M., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.10.012 · Cited by 73 · cited 1×
“Interestingly, the levels of C26:0-LPC, the marker that is used in newborn screening to detect ALD (47, 64), are completely normalized in ALD fibroblasts upon treatment with TO901317.”
BackgroundSelf-citationJaspers, Y. R. J., Ferdinandusse, S., Dijkstra, I. M. E., Barendsen, R. W., van Lenthe, H., Kulik, W., Engelen, M., Goorden, S. M. I., Vaz, F. M., & Kemp, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00690 · Cited by 69
Self-citationC26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man
van de Beek, M.-C., Dijkstra, I. M. E., van Lenthe, H., Ofman, R., Goldhaber-Pasillas, D., Schauer, N., Schackmann, M., Engelen-Lee, J.-Y., Vaz, F. M., Kulik, W., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154597 · Cited by 48
Self-citationStrachan, L. R., Stevenson, T. J., Freshner, B., Keefe, M. D., Miranda Bowles, D., & Bonkowsky, J. L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx249 · Cited by 46 · cited 5×
“A new tool for studies of ALD was provided through generation of a zebrafish abcd1 mutant model (32).”
BackgroundMethodSelf-citationKemp, S., Valianpour, F., Mooyer, P. A. W., Kulik, W., & Wanders, R. J. A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038539 · Cited by 40
Self-citation
Cited by
The physiological functions of human peroxisomes
Wanders, R. J. A., Baes, M., Ribeiro, D., Ferdinandusse, S., & Waterham, H. R. (2023) · Physiological Reviews · doi:10.1152/physrev.00051.2021 · Cited by 228
Self-citationMyelin lipid metabolism and its role in myelination and myelin maintenance
Barnes-Vélez, J. A., Aksoy Yasar, F. B., & Hu, J. (2023) · The Innovation · doi:10.1016/j.xinn.2022.100360 · Cited by 73
Peroxisomal ABC Transporters: An Update
Tawbeh, A., Gondcaille, C., Trompier, D., & Savary, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116093 · Cited by 68
The pathology of X-linked adrenoleukodystrophy: Tissue specific changes as a clue to pathophysiology
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03105-0 · Cited by 20
“Regional heterogeneity and specialization of microglia in the brain and myelum could explain this difference [65].”
BackgroundSelf-citationPeroxisomal defects in microglial cells induce a disease-associated microglial signature
Raas, Q., Tawbeh, A., Tahri-Joutey, M., Gondcaille, C., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Leoni, V., Bellanger, E., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1170313 · Cited by 16
“Single or double 1 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE200022 Abbreviations: AA, Arachidonic acid; ABC, ATP-binding cassette; ACOX1, Acyl-CoA oxidase 1; AMN, Adrenomyeloneuropathy; cALD, Cerebral adrenoleukodystrophy; CRISPR, Clustered regularly interspaced short palindromic repeat; DAM signature, Di…”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Raas, Q., van de Beek, M.-C., Forss-Petter, S., Dijkstra, I. M. E., Deschiffart, A., Freshner, B. C., Stevenson, T. J., Jaspers, Y. R. J., Nagtzaam, L., Wanders, R. J. A., van Weeghel, M., Engelen-Lee, J.-Y., Engelen, M., Eichler, F., Berger, J., Bonkowsky, J. L., & Kemp, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-04-15
- Volume
- 131
- Issue
- 8
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3134705413
- Cited by
- 40
- References
- 30
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.